Researchers unlock mechanism of drug resistance in aggressive breast cancer
Saturday, January 21, 2017 - 10:11
in Health & Medicine
Scientists report findings of how triple negative breast cancer cells are able to bypass treatment with trametinib, a U.S. Food and Drug Administration-approved drug that belongs to a class of commonly used anti-cancer drugs called kinase inhibitors. The researchers also reported findings from laboratory models of breast cancer testing a potential treatment approach that could prevent the onset of resistance.